U.S. Markets open in 1 hr 22 mins
  • S&P Futures

    4,381.75
    -30.00 (-0.68%)
     
  • Dow Futures

    34,859.00
    -115.00 (-0.33%)
     
  • Nasdaq Futures

    14,870.25
    -167.50 (-1.11%)
     
  • Russell 2000 Futures

    2,224.40
    -13.10 (-0.59%)
     
  • Crude Oil

    73.43
    -0.19 (-0.26%)
     
  • Gold

    1,827.90
    -3.30 (-0.18%)
     
  • Silver

    25.55
    -0.24 (-0.92%)
     
  • EUR/USD

    1.1891
    -0.0006 (-0.0476%)
     
  • 10-Yr Bond

    1.2690
    0.0000 (0.00%)
     
  • Vix

    19.18
    +0.87 (+4.75%)
     
  • GBP/USD

    1.3965
    +0.0007 (+0.0531%)
     
  • USD/JPY

    109.6660
    +0.2050 (+0.1873%)
     
  • BTC-USD

    38,749.33
    -899.04 (-2.27%)
     
  • CMC Crypto 200

    920.88
    -9.48 (-1.02%)
     
  • FTSE 100

    7,019.12
    -59.30 (-0.84%)
     
  • Nikkei 225

    27,283.59
    -498.83 (-1.80%)
     

Compugen's COM701 Shows Treatment Durability Beyond One Year in Solid Tumor Patients

·1 min read
  • Compugen Ltd (NASDAQ: CGEN) has announced updated data from its Phase 1 dose-escalation and expansion study of COM701 as a monotherapy and in a dose-escalation combination study with Bristol-Myers Squibb & Co's (NYSE: BMS) Opdivo (nivolumab).

  • Data were presented at the ASCO 2021 Annual Meeting.

  • COM701 and Opdivo combination was well-tolerated with no reported dose-limiting toxicities up to the fifth and final dose cohort.

  • The disease control rate (DCR) was 66.7% with best responses of complete response (CR) 6.7%, partial response (PR) 6.7% (N=1) and stable disease (SD) 53.3%.

  • Previously reported patient with anal squamous cell carcinoma with confirmed CR remains on treatment at 96 weeks (22 months).

  • Previously reported patient with renal cell carcinoma with the best response of SD remains on treatment at 75 weeks.

  • A patient with microsatellite stable (MSS)-colorectal cancer with durable confirmed partial response previously reported remained on study treatment for 44 weeks.

  • In monotherapy arm, DCR was 47.2% (N=17) with best responses of PR 2.7% (N=1) and SD) 44.4% (N=16).

  • Previously reported patient with primary peritoneal cancer (platinum-resistant, MSS) with confirmed PR remains on study treatment at 79 weeks (18 months).

  • Peripheral blood assessment showed immune activation as measured by immune cell proliferation and IFNγ induction before tumor shrinkage.

  • Price Action: CGEN shares are up 0.76% at $8 during the premarket session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.